Journal of Clinical Endocrinology & Metabolism, Vol 80, 3381-3383, Copyright © 1995 by Endocrine Society

ARTICLES

The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess

VR Obeyesekere, P Ferrari, RK Andrews, RC Wilson, MI New, JW Funder and ZS Krozowski
Laboratory of Molecular Hypertension, Baker Medical Research Institute, Melbourne, Australia.

The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) inactivates glucocorticoids in the kidney and thus permits aldosterone to occupy the non-selective mineralocorticoid receptor in epithelial tissues. We have recently described a C to T transition in the HSD11B2 gene which results in an arginine to cysteine mutation (R337C) in the 11 beta HSD2 enzyme in a consanguineous family with three siblings suffering from Apparent Mineralocorticoid Excess (AME). In the present study we have examined the metabolism of cortisol in mammalian cells transfected with plasmids expressing the wild type and mutant enzymes. In whole cells the Km of the normal enzyme was 110nM, while the enzyme containing the R337C mutation displayed a Km of 1010nM. Further experiments revealed that the mutant was totally inactive in cell free preparations, suggesting that it has additional properties which may compromise its activity in whole cells.

This article has been cited by other articles:

				A. G. Atanasov, I. D. Ignatova, L. G. Nashev, B. Dick, P. Ferrari, F. J. Frey, and A. Odermatt Impaired Protein Stability of 11beta-Hydroxysteroid Dehydrogenase Type 2: A Novel Mechanism of Apparent Mineralocorticoid Excess J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1262 - 1270. [Abstract] [Full Text] [PDF]

				G. Morineau, V. Sulmont, R. Salomon, B. Fiquet-Kempf, X. Jeunemaitre, J. Nicod, and P. Ferrari Apparent Mineralocorticoid Excess: Report of Six New Cases and Extensive Personal Experience J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3176 - 3184. [Abstract] [Full Text] [PDF]

				J. M. Paterson, J. R. Seckl, and J. J. Mullins Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R642 - R652. [Abstract] [Full Text] [PDF]

				C. A. Carvajal, A. A. Gonzalez, D. G. Romero, A. Gonzalez, L. M. Mosso, E. T. Lagos, M. d. P. Hevia, M. P. Rosati, T. O. Perez-Acle, C. E. Gomez-Sanchez, et al. Two Homozygous Mutations in the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene in a Case of Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2501 - 2507. [Abstract] [Full Text] [PDF]

				R. Andrew, K. Smith, G. C. Jones, and B. R. Walker Distinguishing the Activities of 11{beta}-Hydroxysteroid Dehydrogenases in Vivo Using Isotopically Labeled Cortisol J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 277 - 285. [Abstract] [Full Text] [PDF]

				M. I. New and R. C. Wilson Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess PNAS, October 26, 1999; 96(22): 12790 - 12797. [Abstract] [Full Text] [PDF]

				B. S. Nunez, F. M. Rogerson, T. Mune, Y. Igarashi, Y. Nakagawa, G. Phillipov, A. Moudgil, L. B. Travis, M. Palermo, C. Shackleton, et al. Mutants of 11{beta}-Hydroxysteroid Dehydrogenase (11-HSD2) With Partial Activity : Improved Correlations Between Genotype and Biochemical Phenotype in Apparent Mineralocorticoid Excess Hypertension, October 1, 1999; 34(4): 638 - 642. [Abstract] [Full Text] [PDF]

				G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess Hypertension, September 1, 1999; 34(3): 435 - 441. [Abstract] [Full Text] [PDF]

				R. C. Wilson, S. Dave-Sharma, J.-Q. Wei, V. R. Obeyesekere, K. Li, P. Ferrari, Z. S. Krozowski, C. H. L. Shackleton, L. Bradlow, T. Wiens, et al. A genetic defect resulting in mild low-renin hypertension PNAS, August 18, 1998; 95(17): 10200 - 10205. [Abstract] [Full Text] [PDF]

				S. Dave-Sharma, R. C. Wilson, M. D. Harbison, R. Newfield, M. R. Azar, Z. S. Krozowski, J. W. Funder, C. H. L. Shackleton, H. L. Bradlow, J.-Q. Wei, et al. Examination of Genotype and Phenotype Relationships in 14 Patients with Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2244 - 2254. [Abstract] [Full Text]

				P. Mulatero, M. Panarelli, D. Schiavone, A. Rossi, G. Mengozzi, C. J. Kenyon, L. Chiandussi, and F. Veglio Impaired Cortisol Binding to Glucocorticoid Receptors in Hypertensive Patients Hypertension, November 1, 1997; 30(5): 1274 - 1278. [Abstract] [Full Text]

				G. Morineau, A. Boudi, A. Barka, M. Gourmelen, F. Degeilh, N. Hardy, A. Al-Halnak, H. Soliman, J. P. Gosling, R. Julien, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol–cortisone shuttle Clin. Chem., August 1, 1997; 43(8): 1397 - 1407. [Abstract] [Full Text] [PDF]

				K. X. Z. Li, V. R. Obeyesekere, Z. S. Krozowski, and P. Ferrari Oxoreductase and Dehydrogenase Activities of the Human and Rat 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Enzyme Endocrinology, July 1, 1997; 138(7): 2948 - 2952. [Abstract] [Full Text] [PDF]

				T. M. Penning Molecular Endocrinology of Hydroxysteroid Dehydrogenases Endocr. Rev., June 1, 1997; 18(3): 281 - 305. [Abstract] [Full Text]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]

				P. C. White Inherited Forms of Mineralocorticoid Hypertension Hypertension, December 1, 1996; 28(6): 927 - 936. [Abstract] [Full Text]

				T. Mune and P. C. White Apparent Mineralocorticoid Excess : Genotype Is Correlated With Biochemical Phenotype Hypertension, June 1, 1996; 27(6): 1193 - 1199. [Abstract] [Full Text]